Fertility preservation

Mayo Clin Proc. 2011 Jan;86(1):45-9. doi: 10.4065/mcp.2010.0564.

Abstract

Of the estimated 1.5 million men and women who were diagnosed as having cancer in 2010, approximately 10% are younger than 45 years. For these individuals, cancer treatment can be lifesaving but can permanently affect reproductive capacity. The American Society of Clinical Oncology has recommended that oncologists discuss the possibility of infertility with reproductive-age cancer patients and offer referral for fertility preservation consultation and therapy. Fertility preservation is an emerging field that offers treatment aimed at protecting future reproductive ability for individuals with cancer or other serious illnesses. Although fertility preservation strategies vary by patient age and sex, many allow patients to store gametes or reproductive tissues for potential future use to create offspring. As an emerging discipline, many questions remain about the role of fertility preservation. We performed a MEDLINE search from 1950 to June 2010 using the following MeSH terms: amenorrhea; antineoplastic agents; ovarian failure; premature; infertility, female; fertility preservation; infertility, male; adolescent and cancer; child and cancer; cryopreservation; and reproductive technologies, assisted. Studies considered for inclusion included those written in English and published before June 2010.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Cryopreservation
  • Decision Making
  • Female
  • Humans
  • Infertility, Female / etiology*
  • Infertility, Female / prevention & control*
  • Infertility, Male / etiology*
  • Infertility, Male / prevention & control*
  • Male
  • Medical Oncology
  • Neoplasms / therapy*
  • Radiation Protection
  • Radiotherapy / adverse effects
  • Reproductive Techniques, Assisted
  • United States

Substances

  • Antineoplastic Agents